Table 1.

Complement‐based therapeutic targets and their potential applications in organ transplantation.

Molecular mediators	Mechanism of action	Experimental/clinical studies
Eculizumab	C5, abrogate terminal complement activation	Human (ClinicalTrials.gov Identifiers, NCT02013037, NCT01327573, NCT02113891)
C1‐INH (Berinert) (CINRYZE)	Prevent complement initiation via the classical and lectin pathways	Human (ClinicalTrials.gov Identifiers: NCT02134314, NCT01134510, NCT01035593, NCT01147302)
TP‐10 (sCR1)	Inactivate C3a and C5a convertases	Human (a randomized, placebo‐controlled trial in lung transplantation)
CR2‐FH	Inhibits alternative complement pathway	Mice (heart transplants)
CR2‐Crry	Inhibits all complement pathways	Mice (heart and trachea transplants)
NOX‐D19, NOX‐D20, NOX‐D21	Specifically inhibits complement component C5a	Mice (trachea transplants)
Y‐CVF	A C3 inhibitor	Non‐human primates